» Articles » PMID: 34501434

Comparing Outcomes in Asymptomatic and Symptomatic Atrial Fibrillation: A Systematic Review and Meta-Analysis of 81,462 Patients

Overview
Journal J Clin Med
Specialty General Medicine
Date 2021 Sep 10
PMID 34501434
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In atrial fibrillation (AF) patients, the presence of symptoms can guide the decision between rate or rhythm control therapy, but it is still unclear if AF-related outcomes are determined by symptomatic status of their clinical presentation.

Methods: We performed a systematic review and metanalysis following the PRISMA recommendations on available studies that compared asymptomatic to symptomatic AF reporting data on all-cause mortality, cardiovascular death, and thromboembolic events (TEs). We included studies with a total number of patients enrolled equal to or greater than 200, with a minimum follow-up period of six months.

Results: From the initial 5476 results retrieved after duplicates' removal, a total of 10 studies were selected. Overall, 81,462 patients were included, of which 21,007 (26%) were asymptomatic, while 60,455 (74%) were symptomatic. No differences were found between symptomatic and asymptomatic patients regarding the risks of all-cause death (odds ratio (OR) 1.03, 95% confidence interval (CI) 0.81-1.32), and cardiovascular death (OR 0.87, 95% CI 0.54-1.39). No differences between symptomatic and asymptomatic groups were evident for stroke (OR 1.22, 95% CI 0.77-1.93) and stroke/TE (OR 1.06, 95% CI 0.86-1.31) risks.

Conclusions: Mortality and stroke/TE events in AF patients were unrelated to symptomatic status of their clinical presentation. Adoption of management strategies in AF patients should not be based on symptomatic clinical status.

Citing Articles

Wearables and Atrial Fibrillation: Advances in Detection, Clinical Impact, Ethical Concerns, and Future Perspectives.

Francisco A, Pascoal C, Lamborne P, Morais H, Goncalves M Cureus. 2025; 17(1):e77404.

PMID: 39949464 PMC: 11822239. DOI: 10.7759/cureus.77404.


Adherence to integrated care using the 'Atrial fibrillation Better Care' pathway in asymptomatic patients with atrial fibrillation improves clinical outcomes: A report from the prospective COOL-AF registry.

Kaolawanich Y, Winijkul A, Yindeengam A, Sairat P, Lip G, Krittayaphong R Heliyon. 2025; 11(1):e41586.

PMID: 39850421 PMC: 11755037. DOI: 10.1016/j.heliyon.2024.e41586.


Spotlight on the 2024 ESC/EACTS management of atrial fibrillation guidelines: 10 novel key aspects.

Rienstra M, Tzeis S, Bunting K, Caso V, Crijns H, De Potter T Europace. 2024; 26(12).

PMID: 39716733 PMC: 11666470. DOI: 10.1093/europace/euae298.


A danish healthcare-focused economic evaluation of first-line cryoballoon ablation versus antiarrhythmic drug therapy for the treatment of paroxysmal atrial fibrillation.

Hansen M, Moss J, Tonnesen J, Johansen M, Kuniss M, Ismyrloglou E BMC Cardiovasc Disord. 2024; 24(1):363.

PMID: 39014312 PMC: 11251117. DOI: 10.1186/s12872-024-04024-5.


Great debate: device-detected subclinical atrial fibrillation should be treated like clinical atrial fibrillation.

Sanders P, Svennberg E, Diederichsen S, Crijns H, Lambiase P, Boriani G Eur Heart J. 2024; 45(29):2594-2603.

PMID: 38935554 PMC: 11297513. DOI: 10.1093/eurheartj/ehae365.


References
1.
Magnussen C, Niiranen T, Ojeda F, Gianfagna F, Blankenberg S, Njolstad I . Sex Differences and Similarities in Atrial Fibrillation Epidemiology, Risk Factors, and Mortality in Community Cohorts: Results From the BiomarCaRE Consortium (Biomarker for Cardiovascular Risk Assessment in Europe). Circulation. 2017; 136(17):1588-1597. PMC: 5657474. DOI: 10.1161/CIRCULATIONAHA.117.028981. View

2.
Boriani G, Laroche C, Diemberger I, Fantecchi E, Popescu M, Rasmussen L . Asymptomatic atrial fibrillation: clinical correlates, management, and outcomes in the EORP-AF Pilot General Registry. Am J Med. 2014; 128(5):509-18.e2. DOI: 10.1016/j.amjmed.2014.11.026. View

3.
Siontis K, Gersh B, Killian J, Noseworthy P, McCabe P, Weston S . Typical, atypical, and asymptomatic presentations of new-onset atrial fibrillation in the community: Characteristics and prognostic implications. Heart Rhythm. 2016; 13(7):1418-24. PMC: 4802367. DOI: 10.1016/j.hrthm.2016.03.003. View

4.
Boriani G, Vitolo M, Imberti J, Potpara T, Lip G . What do we do about atrial high rate episodes?. Eur Heart J Suppl. 2020; 22(Suppl O):O42-O52. PMC: 7753882. DOI: 10.1093/eurheartj/suaa179. View

5.
Komatsu T, Tachibana H, Sato Y, Ozawa M, Kunugida F, Nakamura M . Efficacy of antiarrhythmic drug therapy in preventing recurrence of atrial fibrillation and long-term cardiovascular prognosis in patients with asymptomatic paroxysmal atrial fibrillation. Int Heart J. 2010; 51(2):98-104. DOI: 10.1536/ihj.51.98. View